[Immunopathophysiologic characteristics of early pregnancy in women with recurrent miscarriage].
The lymphocyte subsets, activation marker expression and activity of ConA-treated lymphocytes have been studied in 58 patients with a history of unexplainable pregnancy loss (UPL) and 22 normal pregnant women (control) in 4-7 weeks of pregnancy. The increase of CD16/56+ cell level and CD4+/ CD8+ ratio and decrease of CD19+ cell level have been found in peripheral blood of UPL patients in comparison with control. The expression of HLA-DR was upregulated on CD3+ and CD8+ cells and the expression of CD25 was downregulated on CD3+, CD4+, CD8+, and CD16/56+ cells in UPL women. According to correlation analysis results, low expression of CD25 was related to a low expression of CD8 on NK, high expression of CD45RA on CD4+ helper cells, high expression of HLA-DR on CD8+ cytotoxic cells. High frequency of ConA-induced activation, low frequency of ConA-induced suppression and low suppressive activity of ConA-induced lymphocyte were found in UPL patients compared to control.


CONCLUSIONS
women with UPL have disorders in feto-maternal recognition in early pregnancy that led to a development of the inadequate immune response to fetus realized as a defect of NK activation, deficiency of T-cytotoxic cell limitation and memory helper cell generation, downregulation of TR cells and suppressor function.
Radysh
T V
TV
Institute of Pediatrics, Obstetrics and Gynecology, Academy of Medical Science of Ukraine, Kyiv.
Chernyshov
V P
VP
D000026:Abortion, Habitual / Q000097:blood / Q000276:immunology*; D015703:Antigens, CD / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003208:Concanavalin A / Q000494:pharmacology; D005260:Female; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D007156:Immunologic Memory / Q000276:immunology; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D011247:Pregnancy; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology
D015703:Antigens, CD; D015415:Biomarkers; D006684:HLA-DR Antigens; D003208:Concanavalin A